KYOWA KIRIN

July 26, 2013

Kyowa Hakko Kirin Co., Ltd.

Appendix to the Fiscal 2013 Interim Consolidated Financial Statements

Interim results for Fiscal 2013
(January 1, 2013 - June 30, 2013)

KYOWA KIRIN

Index Page

I. Consolidated Financial Results
1.Trends in consolidated income 1
2.Trends in results by segment 2
3. Other trends 3

II. Consolidated Balance Sheets 4

III. Consolidated Cash Flows 5

IV. Consolidated Subsidiaries and Affiliates 6

V. Kyowa Hakko Kirin Sales of Main Products 7, 8

VI. Segment Information and Main Subsidiaries Operating Profit or Loss
1. Pharmaceuticals segment 9
2. Bio-Chemicals segment 10

VII. R&D Pipeline 11, 12, 13

・This document was made as a supplement to the Kessan Tanshin (financial report) for the first half of Fiscal 2013, the six-month period from January 1, 2013 to June 30, 2013.
・This document contains forward-looking statements based on a member of assumptions and beliefs made by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.
・Figures presented in this document have been rounded down to the nearest whole number.
・The average exchange rate for each period was as follows.

	2012 results				2013 results				2013 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
US $	79	80	79	80	89	94	-	-	95
EURO	104	103	102	103	118	123	-	-	124
GBP	125	126	125	127	141	145	-	-	145

Contact
Kyowa Hakko Kirin Co., Ltd.
Corporate Communications Department
Tel 81 3 3282 0009

I. Consolidated Financial Results

1. Trends in consolidated income

Accumulative

Billions of yen, rounded down

	FY 2012 results				FY 2013 results									FY 2013 forecasts		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change %	Jan - Jun	Change Amount	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Dec	Change Amount	Change %
Net sales	87.1	166.2	244.6	333.1	86.6	99%	169.7	3.4	102%	-	-	-	-	339.0	5.8	102%
Gross Profit	55.0	104.3	154.3	210.6	52.3	95%	105.1	0.8	101%	-	-	-	-			
Selling, general and administrative expenses	36.9	78.7	117.0	157.7	37.8	102%	77.9	(0.7)	99%	-	-	-	-			
Operating income (prior to amortization of goodwill)	20.3	30.2	44.2	62.1	16.7	82%	31.8	1.5	105%	-	-	-	-	60.2	(1.9)	97%
Operating income	18.0	25.5	37.3	52.9	14.4	80%	27.1	1.5	106%	-	-	-	-	51.0	(1.9)	96%
Other income	1.6	1.4	1.9	4.1	1.0	63%	2.4	0.9	169%	-	-	-	-			
Other expenses	3.1	3.9	6.6	8.0	0.6	22%	3.0	(0.8)	78%	-	-	-	-			
Ordinary income	16.5	23.0	32.5	49.0	14.8	90%	26.5	3.4	115%	-	-	-	-	48.0	(1.0)	98%
Extraordinary income	-	-	-	-	3.8	-	4.4	4.4	-	-	-	-	-			
Extraordinary expenses	0.3	0.3	1.2	3.9	-	-	0.1	(0.2)	38%	-	-	-	-			
Net income before income taxes	16.2	22.7	31.3	45.0	18.6	115%	30.8	8.0	136%	-	-	-	-	49.0	3.9	109%
Corporate, local and enterprise taxes	7.7	11.2	15.8	20.6	8.1	106%	13.1	1.9	117%	-	-	-	-			
Income from minority interests	0.0	0.0	0.0	0.2	0.0	52%	0.0	0.0	135%	-	-	-	-			
Net income	8.5	11.5	15.4	24.1	10.4	123%	17.6	6.1	153%	-	-	-	-	28.0	3.8	116%
Comprehensive income	15.0	13.3	18.3	34.7	16.8	112%	28.9	15.5	217%	-	-	-	-			
EPS prior to amortization of goodwill (¥/share)	19.66	29.40	40.79	61.00	23.39	119%	40.75	11.34	139%	-	-	-	-	68.06	7.06	112%

*1 "Prior to amortization of goodwill" refers to profits prior to the deduction of amortization of the goodwill *arising on the reverse acquisition in April 2008 (Kirin Pharma share transfer).
（Note: This adjustment does not include goodwill amortization in respect of the acquisition of ProStrakan.）

*2 Fiscal 2013 forecasts that were announced on January 31, 2013 were revised on July 26, 2013 as shown in the fiscal 2013 H1 results report

Quarterly

Bllions of yen, rounded down

	FY 2012 results				FY 2013 results								
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change %	Apr - Jun	Change Amount	Change %	Jul - Sep	Change %	Oct - Dec	Change %
Net sales	87.1	79.1	78.4	88.4	86.6	99%	83.0	3.8	105%	-	-	-	-
Gross Profit	55.0	49.3	50.0	56.3	52.3	95%	52.7	3.4	107%	-	-	-	-
Selling, general and administrative expenses	36.9	41.7	38.3	40.7	37.8	102%	40.0	(1.6)	96%	-	-	-	-
Operating income (Prior to amortization of goodwill)	20.3	9.8	14.0	17.8	16.7	82%	15.0	5.1	152%	-	-	-	-
Operating income	18.0	7.5	11.7	15.5	14.4	80%	12.7	5.1	168%	-	-	-	-
Other income	1.6	(0.2)	0.5	2.2	1.0	63%	1.3	1.5	-	-	-	-	-
Other expenses	3.1	0.7	2.7	1.3	0.6	22%	2.3	1.5	304%	-	-	-	-
Ordinary income	16.5	6.5	9.4	16.4	14.8	90%	11.6	5.1	179%	-	-	-	-
Extraordinary income	-	-	-	-	3.8	-	0.6	0.6	-	-	-	-	-
Extraordinary expenses	0.3	-	0.9	2.7	-	-	0.1	0.1	-	-	-	-	-
Net income before income taxes	16.2	6.5	8.5	13.6	18.6	115%	12.2	5.6	187%	-	-	-	-
Corporate, local and enterprise taxes	7.7	3.4	4.6	4.7	8.1	106%	4.9	1.4	142%	-	-	-	-
Income from minority interests	0.0	0.0	0.0	0.1	0.0	52%	0.0	0.0	219%	-	-	-	-
Net income	8.5	3.0	3.9	8.7	10.4	123%	7.1	4.1	239%	-	-	-	-
EPS prior to amortization of goodwill (¥/share)	19.66	9.72	11.38	20.23	23.39	119%	17.36	7.64	179%	-	-	-	-

I. Consolidated Financial Results

2. Trends in results by segment

Accumulative

Billions of yen, rounded down

		FY 2012 results				FY 2013 results									FY 2013 forecasts		
		Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change %	Jan - Jun	Change Amount	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Dec	Change Amount	Change %
Net sales		87.1	166.2	244.6	333.1	86.6	99%	169.7	3.4	102%	-	-	-	-	339.0	5.8	102%
	Pharmaceuticals	67.2	127.5	189.4	259.3	67.4	100%	129.9	2.3	102%	-	-	-	-	258.0	(1.3)	99%
	Bio-Chemicals	20.5	40.0	57.4	76.9	19.9	97%	41.2	1.1	103%	-	-	-	-	84.0	7.0	109%
	Total	87.8	167.6	246.9	336.3	87.4	100%	171.1	3.4	102%	-	-	-	-	342.0	5.6	102%
	Eliminations	(0.6)	(1.3)	(2.2)	(3.1)	(0.7)	-	(1.4)	(0.0)	-	-	-	-	-	(3.0)	0.1	-
Operating income		18.0	25.5	37.3	52.9	14.4	80%	27.1	1.5	106%	-	-	-	-	51.0	(1.9)	96%
	**Before goodwill amortization*	*20.3*	*30.2*	*44.2*	*62.1*	*16.7*	*82%*	*31.8*	*1.5*	*105%*	-	-	-	-	*60.2*	*(1.9)*	*97%*
	Pharmaceuticals	16.7	23.5	35.1	50.7	13.0	78%	24.1	0.5	103%	-	-	-	-	45.0	(5.7)	89%
		18.8	*27.8*	*41.5*	*59.3*	*15.2*	81%	28.4	0.5	102%	-	-	-	-	*53.6*	(5.7)	90%
	Bio-Chemicals	1.3	2.0	2.2	2.1	1.4	114%	*3.1*	*1.0*	*152%*	-	-	-	-	6.0	3.8	282%
		1.4	*2.3*	*2.6*	*2.7*	*1.6*	*112%*	*3.4*	*1.0*	*145%*	-	-	-	-	*6.6*	*3.8*	*241%*
	Total	18.0	25.5	37.3	52.8	14.5	81%	27.2	1.6	106%	-	-	-	-	51.0	(1.8)	96%
		20.3	*30.1*	*44.2*	*62.1*	*16.8*	*83%*	*31.8*	*1.6*	*106%*	-	-	-	-	*60.2*	*(1.8)*	*97%*
	Eliminations	0.0	0.0	0.0	0.0	(0.0)	-	(0.0)	(0.0)	-	-	-	-	-	-	(0.0)	-

*The Other segment has been discontinued from 2013. As a result, figures for 2012 results have been restated in accordance with the 2013 revised segmental classification.

Quarterly

Billions of yen, rounded down

		FY 2012 results				FY 2013 results								
		Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change %	Apr - Jun	Change Amount	Change %	Jul - Sep	Change %	Oct - Dec	Change %
Net sales		87.1	79.1	78.4	88.4	86.6	99%	83.0	3.8	105%	-	-	-	-
	Pharmaceuticals	67.2	60.3	61.8	69.8	67.4	100%	62.5	2.1	104%	-	-	-	-
	Bio-Chemicals	20.5	19.4	17.4	19.4	19.9	97%	21.2	1.7	109%	-	-	-	-
	Total	87.8	79.8	79.3	89.3	87.4	100%	83.7	3.8	105%	-	-	-	-
	Eliminations	(0.6)	(0.6)	(0.9)	(0.8)	(0.7)	-	(0.6)	(0.0)	-	-	-	-	-
Operating income		18.0	7.5	11.7	15.5	14.4	80%	12.7	5.1	168%	-	-	-	-
	**Before goodwill amortization*	*20.3*	*9.8*	*14.0*	*17.8*	*16.7*	*82%*	*15.0*	*5.1*	*152%*	-	-	-	-
	Pharmaceuticals	16.7	6.7	11.5	15.6	13.0	78%	11.0	4.2	163%	-	-	-	-
		18.8	*8.9*	*13.7*	*17.7*	*15.2*	81%	13.2	4.2	148%	-	-	-	-
	Bio-Chemicals	1.3	0.7	0.1	(0.0)	1.4	114%	1.6	0.8	220%	-	-	-	-
		1.4	*0.8*	*0.3*	*0.0*	*1.6*	*112%*	*1.7*	*0.8*	*199%*	-	-	-	-
	Total	18.0	7.5	11.7	15.5	14.5	81%	12.6	5.1	169%	-	-	-	-
		20.3	*9.8*	*14.0*	*17.8*	*16.8*	*83%*	*15.0*	*5.1*	*152%*	-	-	-	-
	Eliminations	0.0	0.0	0.0	0.0	(0.0)	-	0.0	0.0	151%	-	-	-	-

(2) Regional sales

Billions of yen, rounded down

		FY 2012 results								FY 2013 results							
		Jan - Mar	Percentage of consolidated sales	Jan - Jun	Percentage of consolidated sales	Jan - Sep	Percentage of consolidated sales	Jan - Dec	Percentage of consolidated sales	Jan - Mar	Percentage of consolidated sales	Jan - Jun	Percentage of consolidated sales	Jan - Sep	Percentage of consolidated sales	Jan - Dec	Percentage of consolidated sales
Japan sales		68.9	79.1%	128.8	77.5%	189.9	77.6%	260.5	78.2%	66.1	76.3%	127.7	75.3%	-	-	-	-
Overseas sales		18.1	20.9%	37.3	22.5%	54.7	22.4%	72.6	21.8%	20.5	23.7%	41.9	24.7%	-	-	-	-
	America	4.6	5.3%	10.0	6.1%	15.0	6.2%	21.2	6.4%	5.2	6.0%	11.1	6.6%	-	-	-	-
	Europe	8.4	9.7%	16.9	10.2%	24.0	9.8%	30.9	9.3%	9.4	10.9%	18.5	10.9%	-	-	-	-
	Asia	4.9	5.7%	10.0	6.1%	15.2	6.2%	19.8	6.0%	5.7	6.6%	11.8	7.0%	-	-	-	-
	Other regions	0.1	0.1%	0.2	0.2%	0.4	0.2%	0.5	0.2%	0.1	0.2%	0.3	0.2%	-	-	-	-
Total consolidated net sales		87.1	100.0%	166.2	100.0%	244.6	100.0%	333.1	100.0%	86.6	100.0%	169.7	100.0%	-	-	-	-

* Sales classified by region or country based on location of customer.

I. Consolidated Financial Results

3. Other trends

(1) R&D Expenses

Billions of yen, rounded down

	FY 2012 results				FY 2013 results				FY 2013 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
R&D expenses	11.0	22.1	33.6	44.8	10.6	21.0	-	-	42.7
R&D to net sales ratio	12.7%	13.3%	13.8%	13.4%	12.3%	12.4%	-	-	12.6%
Pharmaceuticals	10.3	20.5	31.3	41.3	9.8	19.3	-	-	39.5
R&D to net sales ratio	15.3%	16.1%	16.5%	15.9%	14.7%	14.9%	-	-	15.3%
Bio-Chemicals	0.7	1.5	2.3	3.4	0.7	1.6	-	-	3.2

(2) Capital Expenditure (Tangible fixed assets)

Billions of yen, rounded down

	FY 2012 results				FY 2013 results				FY 2013 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
Capital expenditure	4.1	7.9	14.7	19.7	5.3	9.6	-	-	24.5
Pharmaceuticals	2.1	4.0	7.3	10.3	1.8	4.4	-	-	12.4
Bio-Chemicals	1.9	3.9	7.4	9.4	3.5	5.1	-	-	12.1

(3) Depreciation Expenses (Tangible and intangible fixed assets)

Billions of yen, rounded down

	FY 2012 results				FY 2013 results				FY 2013 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
Depreciation and amortization expenses	4.6	9.6	14.5	20.9	4.8	9.9	-	-	21.7
Amortization of intangible fixed assets	*1.0*	*2.4*	*3.5*	*5.4*	*1.5*	*3.1*	-	-	*6.6*
Pharmaceuticals	3.1	6.6	10.1	14.5	3.3	6.8	-	-	15.1
Amortization of intangible fixed assets	*1.0*	*2.4*	*3.5*	*5.4*	*1.5*	*3.1*	-	-	*6.6*
Bio-Chemicals	1.5	2.9	4.4	6.2	1.5	3.0	-	-	6.6

*Depreciation expenses for intangible fixed assets do not include goodwill amortization expenses

(4) Goodwill Amortization Expenses

Billions of yen, rounded down

	FY 2012 results				FY 2013 results				FY 2013 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
Amortization expenses	3.0	6.0	9.1	12.0	2.8	5.7	-	-	11.5
Reverse acquisition goodwill amortization expenses	*2.3*	*4.6*	*6.9*	*9.2*	*2.3*	*4.6*	-	-	*9.2*
Pharmaceuticals	2.9	5.7	8.6	11.4	2.7	5.4	-	-	10.8
Reverse acquisition goodwill amortization	*2.1*	*4.3*	*6.4*	*8.6*	*2.1*	*4.3*	-	-	*8.6*
Bio-Chemicals	0.1	0.3	0.4	0.6	0.1	0.3	-	-	0.6
Reverse acquisition goodwill amortization	*0.1*	*0.3*	*0.4*	*0.6*	*0.1*	*0.3*	-	-	*0.6*

*Reverse acquisition goodwill amortization expenses" refers to amortization of goodwill arising on the reverse acquisition in April 2008 (Kirin Pharma share transfer).

II. Consolidated Balance Sheets

Billions of yen, rounded down

	2011	2012				2013				
	Dec 31	Mar 31	June 30	Sep 30	Dec 31	Mar 31	June 30	Change previous year end	Sep 30	Dec 31
Assets	658.8	664.7	659.0	656.9	679.3	694.1	691.4	12.0		
Current assets	284.2	289.2	285.4	283.0	303.9	310.0	306.5	2.5		
Cash and deposits	27.0	28.6	27.7	26.5	21.5	23.2	24.8	3.3		
Notes and accounts receivable-trade	99.1	107.4	93.9	92.3	101.5	103.5	98.5	(3.0)		
Inventory assets	58.9	62.5	61.9	62.9	63.4	68.7	70.9	7.4		
Deferred tax assets	8.6	8.9	9.0	9.0	10.3	10.6	10.6	0.2		
Short-term loans receivable	82.9	74.0	84.6	84.0	98.1	97.3	94.1	(4.0)		
Other	7.4	7.5	8.1	8.1	8.8	6.5	7.3	(1.4)		
Noncurrent assets	374.6	375.5	373.6	373.8	375.3	384.0	384.8	9.5		
Property, plant and equipment	122.9	123.9	123.4	126.1	126.8	129.6	130.2	3.3		
Buildings and structures	37.3	36.9	38.3	37.8	40.7	40.5	40.4	(0.2)		
Machinery, equipment and vehicles	19.0	18.3	17.4	16.7	19.3	19.0	19.8	0.4		
Land	53.9	53.9	53.6	53.5	53.3	55.2	54.8	1.4		
Other	12.6	14.7	14.0	17.9	13.3	14.7	15.1	1.8		
Intangible assets	210.6	211.3	209.8	208.2	207.5	214.5	212.9	5.4		
Goodwill	177.2	176.8	172.2	169.9	168.8	166.7	165.2	(3.6)		
Sales rights	29.0	30.3	33.8	34.9	36.2	45.5	45.5	9.3		
Other	4.3	4.0	3.7	3.4	2.4	2.2	2.1	(0.3)		
Investments and other assets	41.0	40.2	40.3	39.4	40.9	39.9	41.7	0.7		
Investment securities	24.8	24.2	23.6	22.5	23.6	22.9	24.7	1.1		
Deferred tax assets	6.6	6.5	7.1	7.3	7.7	6.7	6.3	(1.4)		
Other	9.5	9.4	9.4	9.5	9.5	10.2	10.6	1.0		
Liabilities	118.8	122.7	118.6	117.3	123.4	126.9	112.0	(11.4)		
Current liabilities	78.3	79.9	79.3	77.5	85.7	89.9	77.3	(8.3)		
Notes and accounts payable-trade	27.3	30.3	23.2	24.1	26.3	30.5	23.4	(2.8)		
Short-term loans payable	5.9	6.0	5.8	5.6	5.6	5.7	5.8	0.1		
Accounts payable-other	31.0	23.0	30.1	26.6	29.0	32.5	26.5	(2.4)		
Income taxes payable	7.8	8.7	12.3	9.6	15.7	8.0	12.8	(2.9)		
Provisions	0.9	4.9	0.8	4.8	1.2	5.1	1.2	0.0		
Other	5.2	6.9	6.8	6.5	7.7	7.8	7.4	(0.2)		
Non-current liabilities	40.4	42.7	39.3	39.7	37.6	36.9	34.6	(3.0)		
Long-term loans payable	0.0	0.1	0.0	0.0	-	-	-	-		
Deferred tax liabilities	10.9	11.3	10.8	10.6	11.2	11.3	11.5	0.3		
Provisions	21.4	21.0	20.6	20.4	19.9	19.5	19.6	(0.3)		
Other	7.9	10.2	7.8	8.5	6.4	6.0	3.4	(3.0)		
Net assets	540.0	542.0	540.3	539.6	555.8	567.2	579.3	23.4		
Shareholders' equity	554.8	550.4	553.4	551.9	560.6	565.6	572.8	12.1		
Capital stock	26.7	26.7	26.7	26.7	26.7	26.7	26.7	-		
Capital surplus	512.3	512.3	512.3	512.3	512.3	512.3	512.3	(0.0)		
Retained earnings	34.9	37.9	40.9	39.3	48.1	53.1	60.3	12.2		
Treasury stock	(19.1)	(26.5)	(26.5)	(26.5)	(26.5)	(26.5)	(26.5)	(0.0)		
Accumulated other comprehensive income	(15.9)	(9.5)	(14.2)	(13.1)	(5.7)	0.4	5.2	11.0		
Valuation difference on available-for-sale securities	(3.1)	(1.9)	(2.8)	(2.2)	(2.2)	(0.0)	0.9	3.2		
Foreign currency translation adjustment	(12.8)	(7.6)	(11.3)	(10.9)	(3.5)	0.4	4.2	7.8		
Subscription rights to shares	0.2	0.1	0.1	0.1	0.2	0.2	0.2	0.0		
Minority interests	0.9	0.9	0.9	0.7	0.8	0.9	1.0	0.1		
Total liabilities and net assets	658.8	664.7	659.0	656.9	679.3	694.1	691.4	12.0		

III. Consolidated cash flows

Billions of yen, rounded down

	2011	2012		2013		Breakdown
	Jan-Dec	Jan-Jun	Jan-Dec	Jan-Jun	Change	
Cash flows from operating activities	40.6	31.9	59.1	20.6	(11.2)	
Net income before taxes and minority interests	46.1	22.7	45.0	30.8	8.0	Net income 17.6 Tax expense 13.1
Accumulated depreciation expense	22.8	9.6	20.9	9.9	0.3	
Amortization of goodwill	10.7	6.0	12.0	5.7	(0.3)	
Other non-capital gain or loss	0.2	(0.8)	0.7	(0.8)	(0.0)	
Gain (loss) relating to investing activities	(6.2)	2.9	5.4	(2.2)	(5.2)	Profit (loss) from sale of shares in affiliate companies (2.7)
Increase (decrease) in working capital	(12.8)	(1.5)	(5.8)	(5.5)	(3.9)	Changes in trade receivables 4.5 Changes in inventories (5.6) Changes in trade payables (4.3)
Income taxes paid	(29.0)	(7.6)	(15.9)	(16.5)	(8.9)	
Other	8.7	0.5	(3.1)	(0.6)	(1.2)	
Cash flows from investing activities	18.4	(15.6)	(98.7)	(34.2)	(18.5)	
Acquisition of property, plant and equipment	(16.3)	(7.3)	(17.5)	(10.7)	(3.4)	
Sale of property, plant and equipment	0.1	0.3	0.4	1.6	1.3	
Acquisition of intangible assets	(1.1)	(7.1)	(9.3)	(12.7)	(5.6)	
Acquisition of investment securities	(1.5)	(3.5)	(6.4)	(1.9)	1.5	
Sale and redemption of investment securities	2.2	2.2	2.4	3.7	1.5	
Proceeds from sale of shares in affiliate companies	15.1	0.0	0.0	3.2	3.2	
Acquisition of shares of subsidiaries following changes in scope of consolidation	(36.9)	(0.1)	(0.1)	-	0.1	
Sale of shares of subsidiaries following changes in scope of consolidation	52.7	-	-	-	-	
Net increase (decrease) in short-term loans	0.1	(0.0)	(66.9)	(15.9)	(15.9)	Short-term loan (over 3 months) to Kirin Holdings
Other	3.9	(0.1)	(1.1)	(1.3)	(1.2)	
Cash flows from financing activities	(30.7)	(13.3)	(19.1)	(5.3)	8.0	
Net increase (decrease) of loans	(6.5)	(0.2)	(0.4)	0.3	0.5	
Acquisition of treasury stock	(12.5)	(7.4)	(7.5)	(0.0)	7.4	
Dividends paid	(11.4)	(5.5)	(11.0)	(5.4)	0.0	
Other	(0.1)	(0.0)	(0.1)	(0.0)	0.0	
Translation differences relating to cash and cash equivalents	(0.6)	0.1	1.6	1.0	0.8	
Increase (decrease) in cash and cash equivalents	27.6	3.1	(57.2)	(17.8)	(20.9)	
Cash and cash equivalents at beginning of year	79.8	107.5	107.5	50.3	(57.2)	
Cash and cash equivalents at end of year*	107.5	110.6	50.3	32.5	(78.1)	

*Cash and cash deposits in the consolidated balance sheet, cash and cash equivalents at end of year in consolidated cash flows, and cash reserves at end of year

Cash and deposit accounts	27.0	27.7	21.5	24.8	(2.8)
Fixed deposits in excess of three months	(1.9)	(1.7)	(2.4)	(3.5)	(1.7)
Short-term loans to the parent company not exceeding three months[1]	82.4	84.6	31.1	11.1	(73.5)
Cash and cash equivalents at end of year	107.5	110.6	50.3	32.5	(78.1)
Fixed deposits in excess of three months	1.9	1.7	2.4	3.5	1.7
Short-term loans to the parent company in excess of three months[1]	-	-	67.0	83.0	83.0
Cash reserves at end of year	109.5	112.3	119.7	119.0	6.6

[1] Based on cash management system (CMS) provided by our parent, Kirin Holdings, to each group company.

IV. Consolidated Subsidiaries and Affiliates

(As of March 31, 2013)

Segment	Type	Region	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Japan	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents
			Kyowa Medical Promotion Co., Ltd.	100.0%	Promotion and sales of pharmaceuticals
			Chiyoda Kaihatsu Co., Ltd. *1	100.0%	Distribution, contracting, wholesale and retail and insurance agency business
		The Americas	Kyowa Hakko Kirin America, Inc.	100.0%	Holding company for administration and management of subsidiaries (US)
			BioWa, Inc.	100.0%	Out-licensing of anti-body technology and accelerating research collaborations (US)
			Kyowa Hakko Kirin Pharma, Inc.	100.0%	Development of outsourced pharmaceutical products (US)
			Kyowa Hakko Kirin California, Inc.	100.0%	Generate new candidate substances and develop pharmaceuticals (US)
			Hematech, Inc.	100.0%	(Company to be discontinued)
			ProStrakan Inc.	100.0%	Sales of pharmaceuticals (US)
		Europe	ProStrakan Group plc	100.0%	Supervision and management of special companies (UK)
			Strakan Inernational S.a r.l.	100.0%	Sales, licensing-in and licensing-out of pharmaceuticals (UK)
			Strakan Pharmaceuticals Limited	100.0%	Development of pharmaceuticals (UK)
			ProStrakan Limited	100.0%	Sales of pharmaceuticals (UK)
			ProStrakan Pharma S.A.S	100.0%	Sales of pharmaceuticals (France)
			ProStrakan Farmaceutica SLU	100.0%	Sales of pharmaceuticals (Spain)
			ProStrakan Pharma GmbH	100.0%	Sales of pharmaceuticals (Germany)
			ProStrakan Holdings B.V.	100.0%	Holding company for special companies (Netherlands)
			ProStrakan Pharma B.V.	100.0%	Sales of pharmaceuticals (Netherlands)
			ProStrakan S.r.l.	100.0%	Sales of pharmaceuticals (Italy)
			ProStrakan AB	100.0%	Sales of pharmaceuticals (Sweden)
		Asia	Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.	100.0%	Manufacture and sale of pharmaceuticals (China)
			Kyowa Hakko Kirin Korea Co., Ltd.	100.0%	Sales of pharmaceuticals (Korea)
			Kyowa Hakko Kirin (Taiwan) Co., Ltd.	100.0%	Sales of pharmaceuticals (Taiwan)
			Kyowa Hakko Kirin (Hong Kong) Co., Ltd.	100.0%	Sales of pharmaceuticals (Hong Kong)
			Kyowa Hakko Kirin (Singapore) Pte. Ltd.	100.0%	Research and sale of pharmaceuticals (Singapore)
	Affiliate accounted for by the equity method	Japan	FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.	50.0%	Development, manufacture and sale of biosimilar pharmaceuticals
			Japan Synthetic Alcohol Co., Ltd. *1	33.3%	Manufacture and sale of industrial alcohol
Bio-Chemicals	Consolidated subsidiary	Japan	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and health care products
			Daiichi Fine Chemical Co., Ltd.	100.0%	Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates
			Kyowa Engineering Co., Ltd.	100.0%	Design and installation of plant facilities and equipment
		The Americas	BioKyowa Inc.	100.0%	Manufacture and sale of amino acids (US)
			Kyowa Hakko U.S.A., Inc.	100.0%	Sale and import/export of fine chemicals including amino acids (US)
			Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Holding company for administration and management of US special companies (US)
		Europe	Kyowa Hakko Europe GmbH	100.0%	Sale and import/export of fine chemicals including amino acids (Germany)
			Kyowa Hakko Bio Italia S.r.l.	100.0%	Sale and import/export of fine chemicals including amino acids (Italy)
		Asia	Shanghai Kyowa Amino Acid Co., Ltd.	70.0%	Manufacture and sale of amino acids (China)
			Thai Kyowa Biotechnologies Co., Ltd.	100.0%	Manufacture and sale of amino acids (Thailand)
			Kyowa Hakko (H.K.) Co., Ltd.	100.0%	Sale and import/export of fine chemicals including amino acids (Hong Kong)
			Kyowa Hakko Bio Singapore Pte. Ltd.	100.0%	Sale and import/export of fine chemicals including amino acids (Singapore)

Changes in scope of consolidation resulting in changes in subsidiairies (2013.1.1～2013.6.30)

New: None

Exclusions: One: Kyowa Hakko Wellness (see Note 2)

Notes: 1. As a result of the discontinuation of the 'Other' segment from 2013 Chiyoda Kaihatsu Co., and Japan Synthetic Alcohol Co., Ltd. have been included in the Pharmaceuticals segment.

2. Kyowa Hakko Wellness no longer exists following its merger with Kyowa Hakko Bio on January 1, 2013.

V. Kyowa Hakko Kirin Sales of main products

Accumulative

Billions of yen, rounded down

	FY 2012 results				FY 2013 results									FY 2013 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change %	Jan - Jun	Change Amount	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Dec	Change %
Kyowa Hakko Kirin total	57.8	107.8	159.4	218.1	56.4	98%	106.4	(1.3)	99%	-	-	-	-	208.5	96%
Indication / Product name															
ESA formulation ***Nesp***	13.8	26.8	41.0	58.1	10.6	77%	25.0	(1.8)	93%	-	-	-	-	54.7	94%
ESA formulation ***Espo***	0.9	1.9	2.9	3.9	0.7	71%	1.5	(0.3)	80%	-	-	-	-	3.2	82%
Nesp/Espo	*14.8*	*28.8*	*43.9*	*62.0*	*11.3*	*77%*	*26.5*	*(2.2)*	*92%*	-	-	-	-	*58.0*	*93%*
Secondary hyperparathyroidism ***Regpara***	2.8	6.2	9.5	13.4	3.0	110%	6.9	0.6	111%	-	-	-	-	14.4	107%
Secondary hyperparathyroidism ***Rocaltrol***	0.7	1.6	2.5	3.6	0.7	104%	1.8	0.1	108%	-	-	-	-	3.8	106%
Antiallergenic ***Allelock***	9.9	16.1	21.8	29.9	10.7	109%	15.9	(0.1)	99%	-	-	-	-	27.5	92%
Antiallergenic ***Celtect***	0.5	1.0	1.4	1.9	0.4	89%	0.8	(0.1)	85%	-	-	-	-	1.6	88%
Antiallergic eyedrops ***Patanol***	5.4	6.9	8.5	10.2	9.4	172%	10.1	3.1	146%	-	-	-	-	13.5	132%
G-CSF ***Gran***	2.9	6.4	9.8	13.5	2.5	87%	5.8	(0.5)	91%	-	-	-	-	12.3	91%
Cancer pain ***Fentos***	0.8	2.0	3.2	4.6	1.0	118%	2.3	0.2	115%	-	-	-	-	5.4	116%
Anticancer ***5-FU***	0.6	1.4	2.1	2.8	0.6	90%	1.3	(0.0)	95%	-	-	-	-	2.6	94%
Anticancer ***Navelbine***	0.3	0.6	0.9	1.3	0.2	79%	0.5	(0.1)	82%	-	-	-	-	1.0	80%
Chronic idiopathic thrombocytopenic purpura ***Romiplate***	0.3	0.7	1.2	1.7	0.4	138%	1.1	0.3	142%	-	-	-	-	2.3	130%
Cardiovascular ***Coniel***	4.2	8.5	12.5	17.1	3.5	84%	7.6	(0.9)	89%	-	-	-	-	15.3	90%
Cardiovascular (Hypertension) ***Coversyl***	0.8	1.7	2.5	3.5	0.7	95%	1.6	(0.0)	96%	-	-	-	-	3.2	91%
Cardiovascular ***Inovan / Pre Dopa *1***	0.6	1.1	1.7	2.4	0.4	76%	0.8	(0.2)	76%	-	-	-	-	1.8	77%
Antiepileptic ***Depakene***	2.4	5.2	7.8	10.7	2.3	95%	5.0	(0.1)	97%	-	-	-	-	10.4	98%
Parkinson's disease ***Permax***	0.3	0.8	1.2	1.7	0.3	76%	0.6	(0.2)	74%	-	-	-	-	1.3	77%
Gastrointestinal ***Nauzelin***	1.1	2.2	3.2	4.9	1.0	95%	2.1	(0.1)	95%	-	-	-	-	4.7	94%
Inflammatory bowel disease ***Asacol***	0.8	1.8	2.8	4.1	1.0	135%	2.4	0.6	134%	-	-	-	-	4.9	122%
Exports and Technology Out-Licensing															
Exports	3.1	5.7	7.5	9.4	3.2	103%	5.4	(0.2)	96%	-	-	-	-	9.8	104%
Technology Out-Licensing	8.1	12.0	18.9	24.4	4.8	60%	9.7	(2.2)	81%	-	-	-	-	14.9	61%

*1 Sales of Pre Dopa terminated on February 28, 2013. As a result Inovan/ Pre Dopa from March 2013 are figure for Inovan

V. Kyowa Hakko Kirin Sales of main products

Quarterly

Billions of yen, rounded down

	FY 2012 results				FY 2013 results								
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change %	Apr - Jun	Change Amount	Change %	Jul - Sep	Change %	Oct - Dec	Change %
Kyowa Hakko Kirin total	57.8	49.9	51.6	58.6	56.4	98%	50.0	0.0	100%	-	-	-	-
Indication / Product name													
ESA formulation ***Nesp***	13.8	12.9	14.2	17.0	10.6	77%	14.3	1.3	111%	-	-	-	-
ESA formulation ***Espo***	0.9	0.9	0.9	0.9	0.7	71%	0.8	(0.1)	89%	-	-	-	-
Nesp/Espo	*14.8*	*13.9*	*15.1*	*18.0*	*11.3*	77%	*15.2*	*1.2*	*109%*	-	-	-	-
Secondary hyperparathyroidism ***Regpara***	2.8	3.4	3.3	3.8	3.0	110%	3.8	0.3	111%	-	-	-	-
Secondary hyperparathyroidism ***Rocaltrol***	0.7	0.9	0.9	1.0	0.7	104%	1.0	0.1	111%	-	-	-	-
Antiallergenic ***Allelock***	9.9	6.2	5.7	8.0	10.7	109%	5.2	(0.9)	84%		-	-	-
Antiallergenic ***Celtect***	0.5	0.4	0.3	0.4	0.4	89%	0.4	(0.0)	81%	-	-	-	-
Antiallergic eyedrops ***Patanol***	5.4	1.4	1.6	1.7	9.4	172%	0.6	(0.7)	46%	-	-	-	-
G-CSF ***Gran***	2.9	3.4	3.4	3.7	2.5	87%	3.2	(0.1)	94%	-	-	-	-
Cancer pain ***Fentos***	0.8	1.1	1.1	1.4	1.0	118%	1.3	0.1	112%	-	-	-	-
Anticancer ***5-FU***	0.6	0.7	0.6	0.7	0.6	90%	0.7	(0.0)	100%	-	-	-	-
Anticancer ***Navelbine***	0.3	0.3	0.3	0.3	0.2	79%	0.2	(0.0)	85%	-	-	-	-
Chronic idiopathic thrombocytopenic purpura ***Romiplate***	0.3	0.4	0.4	0.5	0.4	138%	0.6	0.1	145%	-	-	-	-
Cardiovascular ***Coniel***	4.2	4.3	4.0	4.5	3.5	84%	4.0	(0.2)	93%	-	-	-	-
Cardiovascular (Hypertension) ***Coversyl***	0.8	0.9	0.8	0.9	0.7	95%	0.9	(0.0)	96%	-	-	-	-
Cardiovascular ***Inovan / Pre Dopa *1***	0.6	0.5	0.5	0.6	0.4	76%	0.4	(0.1)	76%	-	-	-	-
Antiepileptic ***Depakene***	2.4	2.7	2.5	2.9	2.3	95%	2.7	(0.0)	99%	-	-	-	-
Parkinson's disease ***Permax***	0.3	0.4	0.4	0.4	0.3	76%	0.3	(0.1)	73%	-	-	-	-
Gastrointestinal ***Nauzelin***	1.1	1.1	0.9	1.7	1.0	95%	1.1	(0.0)	94%	-	-	-	-
Inflammatory bowel disease ***Asacol***	0.8	1.0	1.0	1.2	1.0	135%	1.3	0.3	134%	-	-	-	-
Exports and Technology Out-Licensing													
Exports	3.1	2.5	1.8	1.8	3.2	103%	2.2	(0.2)	88%	-	-	-	-
Technology Out-Licensing	8.1	3.8	6.9	5.5	4.8	60%	4.8	1.0	126%	-	-	-	-

*1 Sales of Pre Dopa terminated on February 28, 2013. As a result Inovan/ Pre Dopa from March 2013 are figure for Inovan only.

VI. Segment information and main subsidiaries operating profit or loss

1. Pharmaceuticals segment

(1) Pharmaceuticals segment total

Billions of yen, rounded down

	FY 2012 results				FY 2013 results									FY 2013 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change %	Jan - Jun	Change Amount	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Dec	Change %
Net sales	67.2	127.5	189.4	259.3	67.4	100%	129.9	2.3	102%	-	-		-	258.0	99%
Japan sales	56.9	105.6	157.2	215.9	55.2	97%	105.7	0.0	100%	-	-	-	-	209.7	97%
Overseas sales	10.3	21.9	32.2	43.3	12.1	118%	24.2	2.3	111%	-	-	-	-	48.2	111%
America	2.6	6.4	9.8	14.2	3.3	126%	7.0	0.5	109%	-	-	-	-	13.9	98%
Europe	5.2	10.3	14.6	18.9	5.8	111%	10.9	0.6	106%	-	-	-	-	21.5	113%
Asia and others	2.4	5.1	7.7	10.1	2.9	122%	6.2	1.1	122%	-	-	-	-	12.7	125%
Operating income	16.7	23.5	35.1	50.7	13.0	78%	24.1	0.5	103%	-	-	-	-	45.0	89%

(2) ProStrakan (GBP)

Millions of GBP, rounded down

	FY 2012 results				FY 2013 results									FY 2013 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change %	Jan - Jun	Change Amount	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Dec	Change %
Net sales	29.3	61.4	92.6	129.4	35.7	122%	74.2	12.7	121%	-	-	-	-	153.5	119%
Chemotherapy-induced nausea and vomiting drug ***Sancuso***	2.8	5.9	9.5	12.3	3.0	107%	6.2	0.2	104%	-	-	-	-	13.8	112%
Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. ***Abstral***	7.2	16.3	24.5	33.9	10.5	144%	22.1	5.7	135%	-	-	-	-	44.5	131%
Replacement therapy with testosterone for male hypogonadism ***Tostran***	1.6	2.9	4.3	7.5	1.8	113%	4.9	2.0	170%	-	-	-	-	11.8	157%
Relief of pain associated with chronic anal fissures ***Rectogesic***	2.4	4.8	7.2	10.1	2.9	121%	6.3	1.5	131%	-	-	-	-	12.7	126%
Osteoporosis drug ***Adcal-D3***	5.9	12.5	19.0	26.3	6.7	113%	13.5	0.9	108%	-	-	-	-	28.1	107%
Others	6.0	12.0	18.1	25.8	7.0	117%	14.0	2.0	117%	-	-	-	-	27.6	107%
Product net sales (subtotal)	26.3	54.7	82.8	116.2	32.2	123%	67.2	12.5	123%	-	-	-	-	138.8	119%
Technology Out-Licensing and others	2.9	6.6	9.8	13.1	3.4	116%	6.9	0.2	103%	-	-	-	-	14.7	112%
Gross profit	19.5	40.9	64.4	91.9	27.4	140%	57.0	16.1	139%	-	-	-	-	116.1	126%
Selling, general and administrative expenses *1	18.5	38.2	55.6	72.4	19.3	105%	39.7	1.4	104%	-	-	-	-	77.9	108%
EBIDTA *2	1.0	2.6	8.7	19.5	8.0	785%	17.2	14.6	657%	-	-	-	-	38.2	196%
Goodwill amortization *1	9.8	19.1	29.4	39.4	9.9	101%	19.9	0.7	104%	-	-	-	-	39.8	101%
Operating income	(8.8)	(16.5)	(20.7)	(19.9)	(1.8)	-	(2.6)	13.8	-	-	-	-	-	(1.6)	-

*1 Amortization of goodwill is not included in Selling, general and administrative expenses.
Goodwill amortization= Depreciation + Goodwill amortization

*2 EBITDA＝Operating income + depreciation + goodwill amortization.

*3 Geographical breakdown of sales is as follows:

UK	Europe (excluding UK)	USA	Other
30.6%	43.3%	23.8%	2.3%

(3) Kyowa Medex

Billions of yen, rounded down

	FY 2012 results				FY 2013 results									FY 2013 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change %	Jan - Jun	Change Amount	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Dec	Change %
Net sales	2.7	5.8	8.8	11.9	2.5	92%	5.4	(0.3)	94%	-	-	-	-	11.8	99%
Japan sales	2.0	4.6	7.1	9.7	2.0	99%	4.5	(0.1)	98%	-	-	-	-	9.8	101%
Biochemical Diagnostic Reagent	0.8	1.8	2.9	4.0	0.8	99%	1.8	0.0	100%	-	-	-	-	4.0	101%
Immunological Diagnostic Reagent	1.0	2.2	3.4	4.7	1.0	101%	2.2	(0.0)	100%	-	-	-	-	4.7	101%
Other	0.2	0.5	0.7	0.9	0.2	95%	0.3	(0.1)	78%	-	-	-	-	0.9	98%
Exports	0.6	1.1	1.6	2.2	0.4	71%	0.9	(0.2)	78%	-	-	-	-	2.0	91%
Operating income	0.2	0.5	0.8	1.2	0.0	20%	0.2	(0.3)	42%	-	-	-	-	0.9	80%

VI. Segment information and main subsidiaries operating profit or loss

2. Bio-Chemicals segment

(1) Bio-Chemicals segment total

Billions of yen, rounded down

	FY 2012 results				FY 2013 results									FY 2013 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change %	Jan - Jun	Change Amount	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Dec	Change %
Net sales	20.5	40.0	57.4	76.9	19.9	97%	41.2	1.1	103%	-	-	-	-	84.0	109%
Japan sales	12.7	24.5	35.0	47.7	11.5	91%	23.4	(1.1)	95%	-	-	-	-	48.1	101%
Overseas sales	7.8	15.4	22.4	29.2	8.4	107%	17.7	2.2	114%	-	-	-	-	35.9	123%
America	1.9	3.6	5.2	6.9	1.8	95%	4.1	0.5	114%	-	-	-	-	8.3	119%
Europe	3.2	6.5	9.3	12.0	3.6	113%	7.5	0.9	115%	-	-	-	-	15.0	125%
Asia and others	2.7	5.2	7.8	10.2	2.9	109%	5.9	0.7	114%	-	-	-	-	12.4	122%
Operating income	1.3	2.0	2.2	2.1	1.4	114%	3.1	1.0	152%	-	-	-	-	6.0	282%

(2) Kyowa Hakko Bio Co., Ltd.

Billions of yen, rounded down

	FY 2012 results				FY 2013 results									FY 2013 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change %	Jan - Jun	Change Amount	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Dec	Change %
Net sales	12.9	25.9	38.0	51.2	13.8	107%	27.8	1.9	108%	-	-	-	-	57.7	113%
Japan sales	8.1	16.4	24.2	32.7	8.8	108%	17.8	1.4	109%	-	-	-	-	36.2	111%
Pharmaceutical and industrial materials	3.4	7.0	10.7	14.1	3.8	109%	7.5	0.4	106%	-	-	-	-	14.8	105%
Healthcare	2.2	4.7	7.1	9.3	2.4	108%	5.3	0.6	113%	-	-	-	-	11.6	124%
Other	2.3	4.6	6.4	9.2	2.5	106%	5.0	0.3	107%	-	-	-	-	9.7	106%
Exports	4.7	9.4	13.7	18.5	4.9	105%	10.0	0.5	106%	-	-	-	-	21.4	116%
Operating income	0.5	1.2	1.4	1.1	1.2	227%	2.2	0.9	182%	-	-	-	-	4.2	360%

(3) Daiichi Fine Chemical Co., Ltd.

Billions of yen, rounded down

	FY 2012 results				FY 2013 results									FY 2013 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change %	Jan - Jun	Change Amount	Change %	Jan - Sep	Change %	Jan - Dec	Change %	Jan - Dec	Change %
Net sales	3.7	6.7	8.8	12.8	2.9	77%	5.8	(0.9)	86%	-	-	-	-	12.2	95%
Operating income	0.2	(0.2)	(0.6)	(1.0)	(0.0)	-	(0.2)	0.0	-	-	-	-	-	(0.6)	-

Ⅶ. R&D Pipeline

Filed・Approved

antibody protein small molecule

As of July 19th, 2013

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma, Add-on Therapy (for Untreated Patients)	Filed in JP	In-House	POTELLIGENT®
				Peripheral T/NK-cell Lymphoma			
		KW-2246 Fentanyl citrate Sublingual Tablet	μ-Opioid Receptor Agonist	Cancer Pain	Filed in JP	Licensed from Orexo	
		Granisetron Patch	$5HT_3$ Serotonin Recpter Antagonist	Chemotheraphy induced Nausea and Vomiting	Filed in Asia	Licensed from Solasia Pharma (ProStrakan)	Asia: Singapore and Malaysia
		KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony Stimulating Factor	Chemotherapy induced Febrile Neutropenia	Filed in JP	Kirin-Amgen	
		KRN1493 Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Hypercalcemia with Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism	Filed in JP	Licensed from NPS	
Nephrology		Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Approved in MY February 2013 Approved in TH June 2013	Licensed from NPS	Asia: Philippine and China
					Filed in Asia		
		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Pediatric Renal Anemia	Filed in JP	Kirin-Amgen	
Central Nervous System		KW-6002 Istradefylline Oral	Adenosine A_{2A} Receptor Antagonist	Parkinson's Disease	Filed in US	In-House	
		KW-6485 Topiramate Oral	Antiepileptic Drug	Pediatric Epilepsy	Filed in JP	Licensed from Janssen Research & Development, LLC	

Phase Ⅱ, Phase Ⅲ

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		◎ARQ 197 Tivantinib Oral	c-Met Inhibitor	Lung Cancer (EGF-receptor mutated)	Phase Ⅱ in JP	ArQule	
				Gastric Cancer	Phase Ⅱ in JP and KR		
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Peripheral T-cell Lymphoma	Phase Ⅱ in EU	In-House	POTELLIGENT®
				Adult T-cell Leukemia/Lymphoma	Phase Ⅱ in US and EU		
				Cutaneous T-cell Lymphoma	Phase Ⅲ in US		
		◎KW-2478 Injection	HSP90 inhibitor	Multiple Myeloma	Phase Ⅰ/Ⅱ in UK/US/PH	In-House	
		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Myelodysplastic Syndrome related Anemia	Phase Ⅱ in JP and KR	Kirin-Amgen	
Nephrology		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	Phase Ⅲ in CN	Kirin-Amgen	
		◎RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	CKD in patients with type 2 diabetes	Phase Ⅱ in JP	Reata	
Immunology /Allergy		◎KHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma	Phase Ⅱ in JP and KR	In-House	Being Developed by MedImmune as MEDI-563 Worldwide except in Japan and other Asian Countries POTELLIGENT®
		◎ASKP1240 Injection	Anti-CD40 Fully Human Antibody	Organ Transplant Rejection	Phase Ⅰ in JP Phase Ⅱ in US	In-House	Jointly Developed with Astellas KM mouse
		Z-206 Mesalazine Oral	pH Dependent Controlled Release Tablet	Crohn's Disease	Phase Ⅱ in JP	Licensed from Zeria Pharma.	Jointly Developed with Zeria Pharma
		◎KHK4827 Injection	Anti-IL-17 Receptor Fully Human Antibody	Psoriasis	Phase Ⅲ in JP	Kirin-Amgen	
Central Nervous System		◎KHK6188 Oral	Cannabinoid CB2 Receptor Agonist	Neuropathic Pain	Phase Ⅱ in JP	In-House	
Other		◎KW-3357 Antithrombin Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase Ⅲ in JP Phase Ⅰ in EU	In-House	

Updated since April 17th, 2013 (Area, Stage, Filed, Approved, Launched etc.)

◎ New Molecular Entity

Ⅶ. R&D Pipeline

Ph Ⅰ

antibody protein small molecule

As of July 19th, 2013

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		◎BIW-8962 Injection	Anti-GM2 Humanized Antibody	Cancer	Phase Ⅰ/Ⅱa in KR	In-House	POTELLIGENT®
		◎KRN951 Tivozanib Oral	VEGF Receptor Inhibitor	Cancer	Phase Ⅰ in JP	In-House	Being Developed overseas by AVEO as AV-951
		◎CEP-37250/ KHK2804 Injection	Anti-Tumor Specific Glycoprotein Humanized Antibody	Cancer	Phase Ⅰ in US	Licensed from Teva	Jointly Developed with Teva POTELLIGENT®
		◎KHK2898 Injection	Anti-CD98 Fully Human Antibody	Cancer	Phase Ⅰ in SG	In-House	POTELLIGENT® KM mouse
		◎ARQ 197 Tivantinib Oral	c-Met Inhibitor	Hepatocellular Cancer	Phase Ⅰ in JP	Licensed from ArQule	
Nephrology		◎KHK7580 Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Phase Ⅰ in JP	Licensed from Mitsubishi Tanabe	
Immunology /Allergy		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Asthma	Phase Ⅰ in JP	In-House	POTELLIGENT®
		◎KHK4083 Injection	Immunomodulator	Autoimmune diseases	Phase Ⅰ in CA	In-House	POTELLIGENT® KM mouse
		◎KHK4577 Oral	Anti-inflammatory Agent	Inflammatory disease	Phase Ⅰ in JP	In-House	
Other		◎KRN23 Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemic Rickets/Osteomalacia (XLH)	Phase Ⅰ/Ⅱ in US and CA	In-House	KM mouse

Updated since April 17th, 2013 (Area, Stage, Filed, Approved, Launched etc.)

◎ New Molecular Entity

Updated since April 17th, 2013 (Area, Stage, Filed, Approved, Launched etc.)

Filed・Approved

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma, Add-on Therapy (for Untreated Patients) Peripheral T/NK-cell Lymphoma	Filed in JP	In-House	POTELLIGENT®
		KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony Stimulating Factor	Chemotherapy induced Febrile Neutropenia	Filed in JP	Kirin-Amgen	
		KRN1493 Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Hypercalcemia with Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism	Filed in JP	Licensed from NPS	
Nephrology		Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Approved in MY February 2013 Approved in TH June 2013	Licensed from NPS	

Phase Ⅰ-Ⅲ

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		◎BIW-8962 Injection	Anti-GM2 Humanized Antibody	Cancer	Phase Ⅰ/Ⅱa in KR	In-House	POTELLIGENT®
Nephrology		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	Phase Ⅲ in CN	Kirin-Amgen	

<Appendix> Pipeline of Biosimilar（Fujifilm Kyowa Kirin Biologics）

Phase Ⅰ

As of July 19th 2013

Code Name	Generic Name	Stage	Remarks
FKB327	Adalimumab （fully human anti-TNF-α monoclonal antibody）	Phase Ⅰ in UK	

Updated since Apr. 17th, 2013